STING1 and neoplasm: In addition, STING activation synergizes with VEGFR2 blockade and/or immune checkpoint inhibitors (ICI) leading to normalization of the tumor vasculature and the tumor microenvironment, significant upregulation of adhesion molecules (ICAM-1 and VCAM-1) on ECs, and complete regression of immunotherapy-resistant tumors (90, 94).